Business
Sareum to Present at BIO 2010
Sareum to Present at BIO 2010.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n RNS Number : 3234L Sareum Holdings PLC 05 May 2010 \n\n\n\n\n\n(AIM: SAR)\n\n\n5 May 2010\n\n\n\n\nSAREUM HOLDINGS PLC(\"Sareum\" or the \"Company\") \nSareum to Present at BIO 2010\nSareum (AIM: SAR), the specialist cancer drug discovery business, is pleased to announce that Dr Tim Mitchell, CEO, will present Sareum's Chk1 kinase cancer research programme and SKIL technology platform (\"SKIL\") at the Bio Industry Organisation (\"BIO\") International Convention later today.\nBIO, being held this year in Chicago, USA, is the largest global event for the biotechnology industry. Dr Mitchell's presentation will take place in the UK Innovation Zone, hosted by UK Trade & Investment (\"UKTI\").\nSKIL (Sareum Kinase Inhibitor Library) is Sareum's drug discovery technology platform that has so far produced the Company's Aurora, VEGFR-3 and FLT3 cancer and auto-immune disease research programmes. SKIL has the potential to generate drug research programmes that target many other kinase types.\nSareum's Chk1 kinase cancer research programme is a joint research collaboration with The Institute of Cancer Research and Cancer Research Technology Limited. Novel chemical compounds developed by the collaboration have been shown to increase the effectiveness of current cancer therapeutics in in-vivo cancer models.\nSareum's CEO, Dr Tim Mitchell, commented: \"This is a significant opportunity for us to showcase our drug research programmes and the technology behind them at this prestigious event. As well as presenting the latest progress in our drug programmes, it is important for us to demonstrate the potential for the SKIL technology platform to repeat this success.\"\n\n\n\n\nSareum Holdings plc\n\n\n\n\n\n\n\nTim Mitchell\n\n\n01223 497 700\n\n\n\n\n\n\n\n\n\n\n\n\nMerchant John East Securities Limited (Nomad)\n\n\n\n\nSimon Clements/Bidhi Bhoma\n\n\n020 7628 2200\n\n\n\n\n\n\n\n\n\n\n\n\nHybridan LLP (Broker)\n\n\n\n\n\n\n\nClaire Noyce/Stephen Austin\n\n\n020 7947 4350\n\n\n\n\nNotes for editors: \nAbout Sareum Holdings plc\n \nSareum is a drug discovery company, headquartered in Cambridge UK, that is focused on producing targeted small molecule therapeutics to address unmet medical needs, primarily in cancer.\n \nSareum aims to successfully deliver drug candidates for licensing to pharmaceutical and biotechnology ...